Publication | Closed Access

High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study

Breast OncologyMedicineTrastuzumab-induced CardiotoxicityImmunologyPathologyInflammatory MarkerBreast CancerCancer BiologyHigh-sensitivity C-reactive ProteinOncologyRadiation OncologyCancer ResearchPilot Study